Eli Lilly and Co (LLY, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products. Eli Lilly and Co has a market cap of $129.33 billion; its shares were traded at around $122.09 with a P/E ratio of 39.51 and P/S ratio of 5.21. The dividend yield of Eli Lilly and Co stocks is 1.91%.
For the last quarter Eli Lilly and Co reported a revenue of $6.4 billion, compared with the revenue of $6.2 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $24.6 billion, an increase of 7.4% from last year. For the last five years Eli Lilly and Co had an average revenue growth rate of 2.4% a year.
The reported diluted earnings per share was $3.051 for the year, an increase of -1705.8% from previous year. The Eli Lilly and Co enjoyed an operating margin of 25.19%, compared with the operating margin of 21.56% a year before. The 10-year historical median operating margin of Eli Lilly and Co is 23.10%. The profitability rank of the company is 7 (out of 10).
At the current stock price of $122.09, Eli Lilly and Co is traded at 93.2% premium to its historical median P/S valuation band of $63.20. The P/S ratio of the stock is 5.21, while the historical median P/S ratio is 2.70. The stock gained 59.98% during the past 12 months.
Directors and Officers Recent Trades:
- SVP & President, Lilly Int'l Alfonso G Zulueta sold 4,000 shares of LLY stock on 01/31/2019 at the average price of $120. The price of the stock has increased by 1.74% since.
For the complete 20-year historical financial data of LLY, click here.
